Navigation Links
Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7

IRVINE, Calif., July 31 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS), the worldwide leader in intravascular temperature management (IVTM(TM)) therapies for critically ill patients, today announced that it will hold a conference call to discuss the Company's second quarter results and provide a corporate update. Bill Worthen, president and CEO, will host the call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Thursday, August 7. A press release for the second quarter ended June 30, 2008 will be released following the market close on August 7.

To participate in the live call by telephone, please dial 800-949-2163 from the U.S. or +1-719-785-1756 for international callers. In addition, the live conference call is being webcast and can be accessed via the "Investor Relations" section of the Company's website at Beginning 90 minutes after the conference call concludes, a replay will be available on Alsius' website or by dialing 888-203-1112 from the U.S. or +1-719-457-0820 internationally, and entering passcode 4517103 when prompted. The telephone replay will be available through August 31, 2008.

About Alsius Corporation

Alsius, headquartered in Irvine, Calif., is a medical device company that develops, manufactures and sells proprietary products to precisely control patient temperature in hospital critical care settings. Controlling body temperature, through cooling and warming, is becoming the standard of care for patients in select critical conditions and those undergoing a variety of surgical procedures. Alsius markets a comprehensive suite of catheter-based intravascular temperature management products that address the need for effective, accurate, easy-to-use and cost-effective control of body temperature in critical care patients. For more information, visit

Safe Harbor

This press release may contain statements regarding plans and expectations for the future that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking. Such forward looking statements, based upon the current beliefs and expectations of Alsius' management, are subject to risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The information set forth herein should be read in light of such risks. Additional information concerning such risks and uncertainties are contained in Alsius' filings with the Securities and Exchange Commission, which can be accessed electronically on the Securities and Exchange Commission website at

SOURCE Alsius Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alsius Corporation to Host Fourth Quarter and Year-End 2007 Financial Results Conference Call/Webcast on March 13, 2008
2. Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
6. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
Breaking Biology Technology:
(Date:10/26/2015)... Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern authentication ... , today announced the launch of its latest version ... unified platform enabling organizations to use standards-based authentication that ... Nok Nok S3 Authentication Suite is ideal for organizations ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... Mass., Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ), ... results for its third quarter ended September 30, 2015.  ... quarter of 2015 was $4.0 million, a decrease of 33% compared ... in the third quarter of 2015 was $2.2 million, or $0.10 ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):